BFRI — Biofrontera Inc.

Summary of Biofrontera Inc. Q4 2025 Earnings Call

1. Key Financial Results and Metrics

• Q4 2025 Revenues: $17.1 million, a 36% increase year-over-year, marking the highest quarterly revenue in company history.
• Full-Year 2025 Revenues: $41.7 million, up 12% from $37.3 million in 2024.
• Adjusted EBITDA: Q4 adjusted EBITDA was $4.9 million (29% margin), compared to a negative $1.4 million in Q4 2024. Full-year adjusted EBITDA was negative $10.6 million, an improvement from negative $15.3 million in 2024.
• Net Income: Q4 net income was $5.6 million, a significant turnaround from a net loss of $1.4 million in Q4 2024. Full-year net loss improved to $10.5 million from $17.8 million in 2024.
• Gross Profit Margin: Improved to 82% in Q4, up from 58% in the previous year, primarily due to a new earn-out structure reducing cost of goods sold.

2. Strategic Updates and Business Highlights

• Acquisition of U.S. Rights: Biofrontera acquired all U.S. rights, approvals, and patents for Ameluz and RhodoLED from its former parent company, Biofrontera AG, enhancing its operational control.
• Clinical Progress: Submitted a supplemental NDA for superficial basal cell carcinoma (sBCC) with a PDUFA date set for September 28, 2026. Positive Phase III results for actinic keratosis (AK) on extremities and encouraging Phase II results for acne vulgaris were also reported.
• Sales Growth: Ameluz unit volumes increased to approximately 121,000 tubes for the year, with a strong fourth quarter contributing significantly to revenue growth.

3. Forward Guidance and Outlook

• 2026 Expectations: The company anticipates gross profit margins to stabilize between 80% and 85% throughout 2026, benefiting from the new cost structure. The full annualized benefit of the new agreements is expected to enhance financial performance as the company aims for cash flow breakeven.

4. Bad News, Challenges, or Points of Concern

• Legal Expenses: Increased legal costs related to patent claims have been a burden, with SG&A expenses rising by 12% year-over-year.
• Net Loss: Despite improvements, the company still reported a net loss for the year, indicating ongoing financial challenges.
• Patent Disputes: While there was a favorable ruling against Sun Pharma, ongoing legal challenges could pose risks to market position.

5. Notable Q&A Insights

• Gross Margin Projections: Management indicated that gross margins are expected to start at around 82% in 2026, with potential fluctuations based on product mix.
• Market Position: The company emphasized its unique position as the only entity conducting FDA-controlled clinical studies in photodynamic therapy (PDT) for dermatology in the U.S., which could provide a competitive edge.

This earnings call highlighted a transformative year for Biofrontera Inc., characterized by significant revenue growth, strategic acquisitions, and clinical advancements, while also acknowledging ongoing financial challenges and legal risks.